Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.
Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.